Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (50.0%)
Phase 31 (50.0%)

Trials by Status

terminated133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_3

The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)

NCT00441584
completedphase_2

Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)

NCT00787371
completed

Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)

NCT00725205

Clinical Trials (3)

Showing 3 of 3 trials
NCT00441584Phase 3

The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)

Terminated
NCT00787371Phase 2

Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)

Completed
NCT00725205

Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)

Completed

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3